• The recent report by Ganly et al: • They identified the importance of the: • RTK / RAS /RAF / MAPK and PIK3 / AKT / mTOR pathways in this disease • At least one receptor tyrosine kinase: • Was mutated in 20% of HCC tumors, including: • EGFR (2%) • ERBB2 (11%) • PDGFR (2%) • TSHR (4%) • MET (4%) • RET (4%) • PIK3CA mutations: • Were found in 2% of HCC tumors and were: • Mutually exclusive with PTEN mutations (4%) • TSC1/2 mutations: • Occurred in 6% of tumors • NF1: • Was deleted or mutated in 9% of tumors • Mutations in NRAS, HRAS, or KRAS: • Occurred in 15% of tumors: • NRAS 9% • HRAS 2% • KRAS 4% • Mutations in EIF1AX: • Occurred in 11% of tumors, and mutations in other EIF1, 2, or 3 genes: • Occurred in 9% of tumors • In addition to these mutations: • Genes which are overexpressed due to whole chromosome duplication of chromosome 7 were found, including: • BRAF • RHEB • EIF3B • There is currently a phase II randomized clinical trial of the multiple tyrosine kinase inhibitor sorafenib and the mTOR inhibitor everolimus in patients with widely invasive HCC: • The preliminary evidence has shown a significant response rate for these agents, indicating the importance of this pathway in this cancer
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO
Rodrigo Arrangoiz MS, MD, FACS, FSSO 